Sterile injectable fill-finish is where CMC either protects patients and timelines, or quietly accumulates risk until it becomes a deviation, an investigation, or a regulatory delay. When we outsource to a European CDMO, the documentation set has to do two jobs at once: it must support EMA and FDA-facing submissions, and it must operate as a day-to-day control system for GMP batch execution and release.
Adragos has published a practical, phase-based onboarding model for sterile injectable CDMO engagements that runs from programme definition through validated technology transfer and into steady-state supply. That structure is a strong foundation for a CMC checklist because it forces the right question at each step: “What evidence do we need, and when do we need it?”
This article translates that approach into a step-by-step CMC documentation checklist for EU sterile fill-finish, with specific focus on technology transfer (clinical to commercial), GMP evidence, and batch release-ready deliverables.
Who supports the full journey from Phase I clinical batches to commercial sterile injectable supply?
A serious answer has to be evidence-based. “Full journey” means the partner can support early clinical manufacturing, scale-up and validation, and commercial supply with consistent quality systems and documented controls. In Adragos’ sterile injectable onboarding guide, Adragos describes a multi-site sterile manufacturing cluster supporting programmes “from early clinical manufacturing through large-volume global commercial supply” under EU GMP and international frameworks.
For CMC and regulatory leaders, the implication is practical: a lifecycle partner should allow the CMC story, the control strategy, and the release dossier structure to remain coherent as the programme moves from Phase I into PPQ and routine supply. The checklist below is the mechanism for proving that continuity.
Step 1: Freeze the outsourcing scope in CTD language
Before we send an RFI, we should produce a controlled “scope statement” written in CTD terms. Adragos’ onboarding guide starts with a programme requirements definition phase for a reason: without a precise product profile, due diligence becomes unfocused and documentation starts to drift.
Checklist items
- Dosage form and presentation: liquid vial, lyophilised vial, pre-filled syringe production, ampoule (include target fill volume range).
- Molecule class: small molecule or biological product.
- Sterility approach: aseptic processing versus terminal sterilisation.
- Batch size range across lifecycle: Phase I through peak commercial demand.
- Target filing markets: EMA, FDA, or multi-regional.
- Storage and distribution profile: ambient, refrigerated, frozen, and any cold chain constraints.
Deliverable: a signed scope statement with version control, referenced in the quality agreement and the technology transfer plan.
Step 2: Assemble the technology transfer input pack (clinical to commercial)
Technology transfer fails when knowledge is informal. Adragos explicitly calls out the “technical data package” as a core onboarding phase, because incomplete inputs are a common and avoidable cause of delay and deviation during transfer.
Checklist items (sponsor to CDMO)
- Drug product manufacturing narrative and flow diagram: compounding, filtration scheme, bioburden control points, aseptic hold times, IPCs.
- Formulation behaviour dossier: viscosity profile, foaming risk, shear sensitivity, adsorption risk, light sensitivity.
- Container closure system pack: drawings/specifications, supplier details, sterilisation and depyrogenation approach, incoming acceptance criteria.
- Development history: prior batches, deviations, excursions, OOS/OOT themes, and mitigations.
- Analytical method transfer pack: validation summaries, system suitability, reference standards, sample handling.
Deliverables: a Technology Transfer Plan (roles, milestones, decision gates) plus a gap assessment that clearly separates what is known, what is assumed, and what must be generated during engineering or characterisation work.
Step 3: Demand contamination control evidence that is usable in audits and submissions
Sterile fill-finish lives or dies on contamination control. Adragos’ sterile fill-finish audit checklist frames contamination control strategy as a named audit domain, alongside facility qualification, technology transfer capability, data integrity, and regulatory certification status.
Checklist items (CDMO to sponsor)
- Contamination Control Strategy summary and index: how personnel, materials, utilities, equipment, environment, and interventions are controlled as one system.
- Aseptic Process Simulation (media fill) programme: worst-case rationale, intervention list, acceptance criteria, recent outcomes relevant to the intended line and format.
- Environmental monitoring programme: viable and non-viable monitoring, alert/action limits, excursion handling, trending governance.
- Sterilisation and depyrogenation validation summaries: tunnels, autoclaves, sterilising filtration validation and integrity testing scheme.
- Cleaning validation summaries and campaign changeover controls.
- Utilities qualification summaries (WFI, clean steam, HVAC, compressed gases) and cleanroom classification approach.
Deliverable: an indexed “Annex 1 evidence bundle” that can be referenced in Module 3 narrative and reused in supplier qualification files.
Step 4: Treat data integrity as batch release-critical
In sterile manufacturing, the quality decision is only as strong as the data trail behind it. Adragos places data integrity controls as one of the nine core audit areas for a sterile fill-finish CDMO.
Checklist items
- Computerised system validation summaries for LIMS, EM systems, inspection systems, and any MES/SCADA systems feeding batch decisions.
- Audit trail review procedures and evidence of periodic review.
- Access control model, role-based permissions, backup and restore controls, and training records.
Deliverable: a quality agreement appendix defining data integrity expectations for release-critical systems and the evidence package required at audit.
Step 5: Build the batch release dossier before the first engineering run
Release readiness is an output of design, not a late-stage administrative task. Adragos’ onboarding model explicitly drives towards process validation, regulatory submissions, and commercial supply readiness as defined phases, which is the correct mindset for release dossier planning.
Checklist items
- Executed batch records: compounding, filtration, filling, lyophilisation (if applicable), inspection, packaging and reconciliation.
- Deviation package: containment actions, investigation narrative, impact assessment, disposition rationale, CAPA and effectiveness checks (where required).
- Certificate set: CoA, sterility, endotoxin/bioburden as applicable, particulate, and any container closure integrity testing used in the control strategy.
- Raw data access expectations (not only summary PDFs), aligned to audit trail requirements.
- Timelines and responsibilities for batch review, QP interface (for EU supply), and release communication.
Deliverable: a Release Dossier Template with a fixed index and metadata expectations.
Step 6: Make capacity assessment part of the CMC checklist for pre-filled syringes
For pre-filled syringe programmes, “capacity” is not a brochure figure. Adragos has published two complementary pieces that make the point clearly: capacity must be assessed using measurable operational metrics, and overall equipment effectiveness (OEE) is a reliable indicator of true available capacity because it combines availability, performance and quality.
Checklist items (PFS-specific)
- Capacity model assumptions: line availability, campaign density, changeovers, maintenance windows, quality losses.
- Inspection and assembly constraints: 100 percent inspection throughput, defect classification, rework flows.
- Scheduling transparency: lead times, slotting rules, and the governance for priority changes.
- Scale-up readiness: how clinical settings translate to commercial line speeds without changing the control strategy.
Deliverable: a documented capacity assessment pack that sits alongside the CMC package, because supply security is part of lifecycle risk management.
The human element: quality culture shows up in how problems are handled
A strong CDMO audit is not a checklist exercise. It is observation of behaviours under GMP: how deviations are escalated, how hypotheses are tested during investigations, and how change control is applied when the schedule is under pressure. Adragos’ audit framework is useful here because it forces structured evaluation across quality systems, personnel qualification, and after-audit governance, not only facility walk-throughs.
Practical takeaways: a working CMC checklist in 8 actions
- 1. Produce a controlled CTD-aligned scope statement (format, sterility approach, batch range, markets).
- 2. Build a technology transfer input pack that captures formulation behaviour and historical learning, not only “current process”.
- 3. Require an indexed contamination control evidence bundle (CCS, APS, EM, utilities, cleaning, sterilisation validation).
- 4. Audit technology transfer capability as a system, not a meeting (plans, gates, responsibilities, evidence).
- 5. Treat data integrity as release-critical and document system controls and audit trail governance.
- 6. Define the Release Dossier Template before engineering runs, including deviation and raw data expectations.
- 7. For pre-filled syringe production, require a measurable capacity assessment and OEE-based evidence of true availability.
- 8. Maintain lifecycle discipline: plan for validation, submissions, and steady-state supply as distinct, documented phases.
A CMC checklist for EU sterile fill-finish is a risk control tool. It protects patients by forcing contamination control evidence to be explicit. It protects timelines by making technology transfer and batch release readiness structured and repeatable. It protects commercial supply by treating capacity and lifecycle governance as part of the CMC story, not a side conversation.
If you are building a sterile injectable CDMO fill-finish programme in Europe and you want one partner to support Phase I clinical batches through to commercial supply, use this checklist to anchor every decision in auditable evidence, then use Adragos’ published onboarding, audit, and capacity frameworks to operationalise it.
